skip to Main Content

ASCO Urges Routine dMMR Testing for Second-Line Metastatic Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Based on fresh studies in the setting of metastatic pancreatic cancer, the American Society of Clinical Oncology (ASCO) now recommends routine testing for mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H) for candidates for checkpoint inhibitor therapy.

The updates to the guidelines, which were last reviewed in 2016, include a recommendation for the PD-1 immune checkpoint inhibitor pembrolizumab (Keytruda) for patients who test positive for dMMR or MSI-H. Read more . . . 

Back To Top